Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
Authors:
- Zafer SezerZSZafer Sezer
- Shaikh Terkis Islam PavelShaikh Terkis Islam Pavel
- Ahmet InalAIAhmet Inal
- Hazel YetiskinHYHazel Yetiskin
- Busra KaplanBKBusra Kaplan
- Muhammet Ali UygutMUMuhammet Ali Uygut
- Ahmet Furkan AslanAAAhmet Furkan Aslan
- Adnan BayramABAdnan Bayram
- Mumtaz MaziciogluMMMumtaz Mazicioglu
- Gamze Kalin UnuvarGUGamze Kalin Unuvar
- Zeynep Ture YuceZYZeynep Ture Yuce
- Gunsu AydinGAGunsu Aydin
Open Access
Abstract
Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safety of a third, homologous, open-label booster dose of TURKOVAC, administered 12 weeks after completion of the primary series in a randomized, controlled, double-blind, phase 2 study. Forty-two participants included in the analysis were evaluated for neutralizing antibodies (NAbs) (with microneutralization (MNT50) and focus reduction (FRNT50) tests), SARS-CoV-2 S1 RBD (Spike S1 Receptor Binding Domain), and whole SARS-CoV-2 (with ELISA) IgGs on the day of booster injection and at weeks 1, 2, 4, 8, 16, 24, and 32 thereafter. Antibody titers increased significantly from week 1 and remained higher than the pre-booster titers until at least week 4 (week 8 for whole SARS-CoV-2) (p < 0.05 for all). Seroconversion (titers ≥ 4-fold compared with pre-immune status) persisted 16 weeks (MNT50: 6-fold; FRNT50: 5.4-fold) for NAbs and 32 weeks for S1 RBD (7.9-fold) and whole SARS-CoV-2 (9.4-fold) IgGs. Nine participants (20.9%) tested positive for SARS-CoV-2 RT-PCR between weeks 8 and 32 of booster vaccination; none of them were hospitalized or died. These findings suggest that boosting with TURKOVAC can provide effective protection against COVID-19 for at least 8 weeks and reduce the severity of the disease.Keywords
Funding Information
- Health Institutes of Türkiye (TUSEB) (11484, 9644, 11418)
- Erciyes University (11484, 9644, 11418)
This publication has 41 references indexed in Scilit:
- A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccineJournal of Medical Virology, 2021
- Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnershipsVaccine, 2021
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)The Lancet, 2021
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- COVID-19 vaccines: where we stand and challenges aheadCell Death & Differentiation, 2021
- Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccineEmerging Microbes & Infections, 2021
- SARS-CoV-2 vaccines in developmentNature, 2020
- Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in TurkeyPLOS ONE, 2020
- Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virusVirology Journal, 2013